MedTrace Logo

The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.

NCT06324201 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-10-31

No results posted yet for this study

Summary

Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment, prospectively or retrospectively, to this sub-study per inclusion and exclusion criteria.

Conditions

  • Paroxysmal Atrial Fibrillation

Interventions

DEVICE

Ablation Procedure

Ablation Procedure for paroxysmal atrial fibrillation

Sponsors & Collaborators

  • Biosense Webster, Inc.

    collaborator INDUSTRY

  • Heart Rhythm Clinical and Research Solutions, LLC

    lead OTHER

Principal Investigators

  • Brian Sanchez, MD · J & J Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-27
Primary Completion
2026-03-31
Completion
2028-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06324201 on ClinicalTrials.gov